Key result
Dexrazoxane is highlighted as an advance to prevent anthracycline cardiotoxicity, which becomes uncompensated after a lifetime doxorubicin dose of approximately 450 mg/m2.
Why the study?
Does dexrazoxane prevent cardiotoxicity in children receiving anthracyclines?
Population
Cancer patients, particularly children, receiving anthracyclines (e.g., doxorubicin)
Design
Editorial
Authors
Loading...
Dexrazoxane represents an important advance in preventing the cumulative and irreversible cardiotoxicity associated with anthracycline use in cancer treatment, especially in pediatric populations.
Does dexrazoxane prevent cardiotoxicity in children receiving anthracyclines?
Dexrazoxane represents an important advance in preventing the cumulative and irreversible cardiotoxicity associated with anthracycline use in cancer treatment, especially in pediatric populations.
K. Hellmann (1999) conducted an editorial in Anthracycline-induced cardiotoxicity. Dexrazoxane was evaluated. Dexrazoxane is highlighted as an advance to prevent anthracycline cardiotoxicity, which becomes uncompensated after a lifetime doxorubicin dose of approximately 450 mg/m2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: